Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading

Recent studies have shown synergistic cytotoxic effects of simultaneous Chk1- and Wee1-inhibition. However, the mechanisms behind this synergy are not known. Here, we present a flow cytometry-based screen for compounds that cause increased DNA damage in S-phase when combined with the Wee1-inhibitor MK1775. Strikingly, the Chk1-inhibitors AZD7762 and LY2603618 were among the top candidate hits of 1664 tested compounds, suggesting that the synergistic cytotoxic effects are due to increased S-phase DNA damage. Combined Wee1- and Chk1-inhibition caused a strong synergy in induction of S-phase DNA damage and reduction of clonogenic survival. To address the underlying mechanisms, we developed a novel assay measuring CDK-dependent phosphorylations in single S-phase cells. Surprisingly, while Wee1-inhibition alone induced less DNA damage compared to Chk1-inhibition, Wee1-inhibition caused a bigger increase in S-phase CDK-activity. However, the loading of replication initiation factor CDC45 was more increased after Chk1- than Wee1-inhibition and further increased by the combined treatment, and thus correlated well with DNA damage. Therefore, when Wee1 alone is inhibited, Chk1 suppresses CDC45 loading and thereby limits the extent of unscheduled replication initiation and subsequent S-phase DNA damage, despite very high CDK-activity. These results can explain why combined treatment with Wee1- and Chk1-inhibitors gives synergistic anti-cancer effects.

[1]  M. Broggini,et al.  Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo , 2012, Cell cycle.

[2]  C. Vaziri,et al.  The Chk1-mediated S-phase Checkpoint Targets Initiation Factor Cdc45 via a Cdc25A/Cdk2-independent Mechanism* , 2006, Journal of Biological Chemistry.

[3]  H. Lyng,et al.  Hypoxia‐induced alterations of G2 checkpoint regulators , 2016, Molecular oncology.

[4]  P. C. de Witt Hamer,et al.  WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe , 2011, Clinical Cancer Research.

[5]  V. A. Flørenes,et al.  Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma , 2015, BMC Cancer.

[6]  J. Bartek,et al.  Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage , 2005, Molecular and Cellular Biology.

[7]  R. Syljuåsen,et al.  The Efficacy of CHK1 Inhibitors Is Not Altered by Hypoxia, but Is Enhanced after Reoxygenation , 2013, Molecular Cancer Therapeutics.

[8]  J. Decaprio,et al.  The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. , 2012, Genes & development.

[9]  W. Seghezzi,et al.  Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening , 2011, Molecular Cancer Therapeutics.

[10]  R. Syljuåsen,et al.  Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication , 2011, Nucleic acids research.

[11]  J. T. Caldwell,et al.  CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells , 2014, Journal of Hematology & Oncology.

[12]  N. Mailand,et al.  ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA , 2013, Cell.

[13]  T. Helleday,et al.  Chk1 promotes replication fork progression by controlling replication initiation , 2010, Proceedings of the National Academy of Sciences.

[14]  Hui Zhao,et al.  Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Buchholz,et al.  MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells , 2011, Clinical Cancer Research.

[16]  T. Helleday,et al.  Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase , 2010, The Journal of cell biology.

[17]  K. Klempnauer,et al.  Phosphorylation and activation of B-Myb by cyclin A–Cdk2 , 1997, Current Biology.

[18]  S. Patzke,et al.  Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption , 2012, Molecular and Cellular Biology.

[19]  Christopher B. Black,et al.  Cell-based screening using high-throughput flow cytometry. , 2011, Assay and drug development technologies.

[20]  H. Hirai,et al.  MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil , 2010, Cancer biology & therapy.

[21]  J. Aten,et al.  In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. , 2010, Cancer cell.

[22]  A. Heijink,et al.  Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination , 2013, Oncogene.

[23]  James M. Bogenberger,et al.  CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo , 2014, Haematologica.

[24]  T. Stokke,et al.  Simultaneous measurement of passage through the restriction point and MCM loading in single cells , 2015, Nucleic acids research.

[25]  H. Pospiech,et al.  Cdc45 is limiting for replication initiation in humans , 2016, Cell cycle.

[26]  H. Piwnica-Worms,et al.  Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. , 1992, Science.

[27]  J. Myklebust,et al.  The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  P. Johnston,et al.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy , 2014, Nature Reviews Clinical Oncology.

[29]  E. Boye,et al.  Consequences of abnormal CDK activity in S phase , 2016, Cell cycle.

[30]  D. Haas-Kogan,et al.  WEE1 Kinase As a Target for Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Ashworth,et al.  Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. , 2012, Cancer discovery.

[32]  I. Hoffmann,et al.  Ectopic Expression of Cdc25A Accelerates the G1/S Transition and Leads to Premature Activation of Cyclin E- and Cyclin A-Dependent Kinases , 1999, Molecular and Cellular Biology.

[33]  R. Medema,et al.  Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease , 2011, The Journal of cell biology.

[34]  M. Kirschner,et al.  Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. , 1997, Science.

[35]  A. Eastman,et al.  A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase , 2015, Oncotarget.

[36]  T. Stokke,et al.  The Response of Malignant B Lymphocytes to Ionizing Radiation: Cell Cycle Arrest, Apoptosis and Protection against the Cytotoxic Effects of the Mitotic Inhibitor Nocodazole , 2004, Radiation research.

[37]  L. Cascione,et al.  Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma , 2014, Oncotarget.

[38]  K. Cole,et al.  Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. , 2013, Cancer research.

[39]  S. West,et al.  CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair , 2005, Nature.

[40]  S. Sarkar,et al.  Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation , 2015, Cancer cell.

[41]  E. Krausz,et al.  Cell-based high-content screening of small-molecule libraries. , 2007, Current opinion in chemical biology.

[42]  Y. Pommier,et al.  Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762. , 2012, Cancer research.

[43]  Yair Benita,et al.  Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy , 2013, Molecular Cancer Therapeutics.

[44]  J. Bartek,et al.  Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. , 2003, Cancer cell.

[45]  A. Shevchenko,et al.  Interaction of Chk1 with Treslin negatively regulates the initiation of chromosomal DNA replication. , 2015, Molecular cell.